Todos os estudos
RecrutamentoUso terapêutico (Fase IV)Intervencionista

An Interventional, Prospective Open-Label Study of Immunosuppressive Therapies to Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia (RESTORE)

This study, called RESTORE, is for people with a rare bone condition called Hypophosphatasia. The main medicine for this condition, Asfotase Alfa (STRENSIQ®), sometimes faces a challenge: the body can develop an immune response that makes the medicine less effective over time. This trial is investigating different additional treatments given alongside Asfotase Alfa. The aim is to see if these extra treatments can stop the body from fighting the medicine, helping Asfotase Alfa to work better and improve bone health. Researchers will check people over 100 weeks to see if the combined treatments successfully reduce the immune response and show improvements in their bones, which will be checked with X-rays.

Em resumo

Status
Recrutamento
Fase
Uso terapêutico (Fase IV)
Patrocinador
Alexion Pharmaceuticals Inc.
Meta de inscrição
1
Iniciar
18 Jan 2024

Sobre o que é este estudo?

This study is called RESTORE, and it's looking into ways to improve treatment for a condition called Hypophosphatasia. Hypophosphatasia is a rare disease that affects the bones and teeth, making them weak or soft. The main medicine for this condition is called Asfotase Alfa (you might know it by its brand name, STRENSIQ®), and it helps to strengthen bones.

Sometimes, when people take medicines like Asfotase Alfa, their body's immune system (which normally fights off infections) can start to see the medicine as something foreign and try to get rid of it. This can make the medicine less effective over time. This study wants to find out if giving other medicines alongside Asfotase Alfa can stop this immune reaction from happening or make it less severe. The goal is to help Asfotase Alfa work as well as possible for patients.

The researchers will be carefully checking how participants' bodies react to Asfotase Alfa over about two years. They will also look at X-rays to see if the bones are getting stronger. This study is important because it could lead to better ways to manage Hypophosphatasia and help people get the most benefit from their treatment.

Pontos principais

  • This study is for people with Hypophosphatasia.
  • It aims to improve how well the medicine Asfotase Alfa works.
  • Additional treatments are given to reduce the body's immune response to the main medicine.
  • The study lasts for 100 weeks (about two years) with regular check-ups.
  • It's open to all ages and sexes with Hypophosphatasia.
  • Participation includes blood tests, X-rays, and other health checks.

Quem pode ser elegível?

This study is open to anyone with Hypophosphatasia, regardless of their age or sex. The researchers welcome both men and women, and patients of all ages, to take part.

However, it's important to remember that even if you have Hypophosphatasia, there might be other medical reasons why this particular study isn't suitable for you. For example, your other health conditions or current medications could affect whether you can safely participate.

The best way to find out if this study is right for you is to talk to your doctor. They can review all the detailed requirements and discuss if you meet the specific criteria to join.

Este estudo pode ser adequado para você?

Responda a estas perguntas rápidas para ver se você pode ser elegível. Este é apenas um guia — a decisão final é da equipe de pesquisa.

  1. Do I have Hypophosphatasia?
  2. Am I currently being treated with Asfotase Alfa (STRENSIQ®)?
  3. Am I comfortable with receiving additional medicines as part of treatment?
  4. Can I attend regular appointments, including for blood tests and X-rays, over two years?
  5. Have I discussed this study thoroughly with my doctor?
Responda a todas as perguntas para ver o seu resultado.

O que envolve a participação?

If you decide to join this study, you will continue to receive your usual Asfotase Alfa treatment. In addition, you will be given one or more extra medicines aimed at helping Asfotase Alfa work better. These extra medicines might be given as injections, infusions (drips), or tablets.

Throughout the study, which will last for 100 weeks (about two years), you'll have regular appointments. At these appointments, the study team will take blood and urine samples, carry out physical examinations, measure your vital signs (like blood pressure and heart rate), and perform ECGs (heart tracings). You'll also have X-rays to check on your bone health. If you are given Bortezomib, you may also have special heart scans (echocardiograms) and nerve checks.

Riscos e benefícios potenciais

Participating in this study might offer a potential benefit of improving how well your Asfotase Alfa treatment works, which could lead to better bone health. However, like all medicines, the additional treatments being tested have potential side effects, and there's no guarantee that you will personally benefit. You might experience common side effects, or in rare cases, more serious ones. You will be closely monitored for any reactions during the study. Remember, your participation is completely voluntary, and you have the right to withdraw from the study at any time without affecting your standard care.

Localizações (1)

Algumas localizações dos sites são aproximadas. Estamos melhorando isso — por favor, verifique com a equipe de teste antes de viajar.
  • —
    Não verificado
    França

Perguntas frequentes

What is Hypophosphatasia?

Hypophosphatasia is a rare genetic condition that affects the development of bones and teeth, making them weaker or softer than they should be.

What is Asfotase Alfa (STRENSIQ®)?

It's a medicine used to treat Hypophosphatasia by helping to correct the underlying problem and improve bone strength.

Why would my body fight the medicine?

Sometimes, the body's immune system, which protects against germs, can mistakenly see some medicines as foreign and try to remove them, making the medicine less effective.

Quanto tempo durará o estudo?

The main part of the study will last for 100 weeks, which is about two years.

Will I get my usual medicine during the study?

Yes, you will continue to receive Asfotase Alfa, and the study will add other treatments to see if they help it work better.

Como saber mais

Sempre consulte seu médico ou especialista antes de decidir participar de um estudo.

Interessado em participar?

Registre seu interesse

Compartilhe seus detalhes e a equipe de pesquisa para "An Interventional, Prospective Open-Label Study of Immunosup…" entrará em contato com você se você for elegível. Sempre fale com seu médico antes de concordar em participar.

Discussão

Discussão da comunidade

Desenvolvido pelo nosso fórum em community.patient.info. Por favor, seja respeitoso — isto não é um conselho médico.